NCT03913637 (ForAging) is a NA clinical trial of Strategy Training in Mild Cognitive Impairment, sponsored by University of Pittsburgh.

Who is sponsoring NCT03913637?

NCT03913637 is sponsored by University of Pittsburgh.

What drugs are being tested in NCT03913637?

Interventions in NCT03913637: Strategy Training, Enhanced Usual Care.

What condition does NCT03913637 study?

NCT03913637 studies Mild Cognitive Impairment.

Is NCT03913637 still recruiting?

NCT03913637 is currently completed. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT03913637: ForAging

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Facilitating Optimal Routines in Aging

Completed NA Last updated 4 March 2026

What this trial tests

NA trial testing Strategy Training in Mild Cognitive Impairment in 105 participants. Completed in 30 November 2025.

Timeline

31 July 2019

Primary endpoint
30 November 2025

30 November 2025

Quick facts

Lead sponsor	University of Pittsburgh
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	105
Start date	31 July 2019
Primary completion	30 November 2025
Estimated completion	30 November 2025
Sites	1 location across United States

Drugs / interventions tested

Strategy Training
Enhanced Usual Care

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

University of Pittsburgh

Who can join

60 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Loss of cognitive abilities leading to Alzheimer's disease is progressive and destructive, leaving older adults disabled and unable to recall their past. The number of older adults with Alzheimer's disease is expected to triple by the year 2050, yet little research examines amyloid beta deposition, executive function, and progression of disability. This study will test the influence of a novel and promising non-pharmacological intervention, Strategy Training, on the progression of disability in a sample of 150 older adults with Mild Cognitive Impairment who have the option to complete a Positron Emission Tomography (PET) Imaging with Pittsburgh Compound B (PiB).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Strategy Training

Trials testing the same drug.

NCT06754566 — A Caregiver-Assisted Rehabilitation With Strategy Training (CAR-ST) for Stroke Patients · NA · recruiting
NCT05098730 — Strategy Training and Pets to Promote Stroke Survivor's Cognitive Performance and Community Participation · NA · not yet recruiting
NCT06400147 — Strategy Training for Individuals With Unilateral Neglect · NA · completed
NCT03792061 — Enhancing Community Participation for Stroke Survivors With Cognitive Impairments · NA · active not recruiting
NCT03593876 — Strategy Training for People With Aphasia After Stroke · NA · terminated

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other University of Pittsburgh trials

Trials by the same sponsor.

NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03913637 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing